Thursday, July 19, 2007

Lactic acidosis

I ll have to bring stuffs about it soon

Preparative regimens for hematopoietic cell transplantation

INTRODUCTION — The preparative or conditioning regimen is a critical element in the hematopoietic cell transplant procedure. The purpose of the preparative regimen is twofold:
To provide adequate immunosuppression to prevent rejection of the transplanted graft
To eradicate the disease for which the transplant is being performed.
These goals have traditionally been achieved by delivering maximally tolerated doses of multiple chemotherapeutic agents with nonoverlapping toxicities, with or without radiation. Several novel approaches have been evaluated in an attempt to minimize toxicity. As an example, nonmyeloablative preparative regimens have been used to induce a state of mixed chimerism (defined as the concurrent presence of donor and recipient hematopoietic cells); this can be followed by cellular therapy via the administration of donor lymphocyte infusions. Another alternative is targeted therapy in the form of radiolabeled monoclonal antibodies.
The toxicity associated with preparative regimens and an overview of the more common regimens currently in use will be presented here. The preferred preparative regimen for specific diseases and the approaches to prevention of the other major complications of hematopoietic cell transplantation — graft-versus-host disease — are discussed separately. There are also occasional settings in which transplantation can be performed without prior myeloablation, primarily in children with severe combined immunodeficiency who lack T-cell function [1]. (See "Hematopoietic cell transplantation and gene therapy for immune deficiency").
The term "hematopoietic cell transplantation" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See "Sources of hematopoietic stem cells").
COMMON TOXICITIES — All of the preparative regimens discussed below have side effects that can be life-threatening. In addition to myelotoxicity, other common toxicities include:
Mucositis (see "Oral toxicity associated with chemotherapy")
Nausea and vomiting (see "Prevention and treatment of chemotherapy-induced nausea and vomiting")
Alopecia (See "Chemotherapy-induced alopecia")
Diarrhea (See "Enterotoxicity of chemotherapeutic agents")
Rash
Peripheral neuropathies (See "Neurologic complications of cancer chemotherapy").
Infertility, which can be devastating, is almost universal when using myeloablative regimens. This can be addressed with sperm cryopreservation for male patients, assuming they have adequate sperm number and function. However, oocyte cryopreservation in female patients has generally been unsuccessful.
Pulmonary and hepatic toxicity are also relatively common. As an example, busulfan, which is a component of many preparative regimens, can produce both interstitial lung disease and hepatic venoocclusive disease [2,3]. (See "Pathogenesis and clinical features of hepatic veno-occlusive disease following hematopoietic cell transplantation"). As a result, it is imperative that patients be screened prior to initiating the preparative regimen to avoid unnecessary risk.
Total body irradiation — Long-term complications following total body irradiation (TBI) used as part of a HCT preparative regimen are common. In one study of 186 adults surviving at least one year following TBI and HCT, who were followed for a median time of four years (range 1 to 11 years), the most commonly seen complications included [4]:
Asymptomatic alterations in pulmonary function — 19 percent [5]
Cataract — 15 percent. Surgery was necessary in 57 percent
Sicca syndrome — 13 percent
Hypothyroidism — 6.5 percent. One-half required medical treatment
Thyroiditis — 3 percent.
MYELOABLATIVE PREPARATIVE REGIMENS — A number of myeloablative regimens have been employed at centers throughout the world. They have generally used total body irradiation with or without chemotherapy. These regimens were developed by escalating the dose of either radiation or a particular drug to the maximally tolerated dose. Drugs with nonoverlapping toxicities were employed in an effort to avoid synergistic injury to a particular organ (show table 1).
In all instances, hematopoietic toxicity was ignored and, since this system is the most sensitive to the effects of radiation and/or cytotoxic chemotherapy, all regimens were associated with a high degree of myelotoxicity. The extent to which any particular regimen is in fact myeloablative is very hard to know with certainty. However, delayed bone marrow recovery is undesirable since it would be associated with excessive morbidity and mortality.
There are few randomized trials directly comparing the efficacy of one myeloablative preparative regimen to another, As a result, it is difficult to make direct statements about the suitability of a given preparative regimen in a particular disease setting [6,7].
Radiation-containing regimens — Total body irradiation (TBI) has been the mainstay of preparative regimens since the inception of HCT, based upon early studies in the dog and other animal models. Initial preparative regimens included TBI administered as a single dose using opposing Cobalt-60 sources [8]. At present, TBI-based regimens typically fractionate the radiation and administer the total dose over several days, which helps decrease toxicity and increase tolerability (show table 2) [9]. Partial lung shielding is included in an effort to reduce the potential for irreversible lung injury.
In the initial regimens, TBI was combined with cyclophosphamide (Cy) and this TBI/Cy combination is still widely used. Cyclophosphamide is usually given at a dose of 60 mg/kg of adjusted ideal body weight on each of two successive days [10-12].
The maximally tolerated dose of TBI is approximately 15 Gy. Higher doses produce excessive nonhematologic toxicity, primarily to the lungs, but also to other organs including the heart. Two randomized trials evaluated the efficacy of different doses of TBI (12 and 16 Gy) plus cyclophosphamide, prior to allogeneic HCT in patients with acute myeloid leukemia in first remission and chronic myelogenous leukemia in the chronic phase [13,14]. Decreased relapse rates were observed with the higher TBI dose (eg, 12 versus 35 percent at three years in patients with acute myeloid leukemia), but overall survival was similar due primarily to increased transplant-related mortality at the higher doses (eg, 32 versus 12 percent at three years) [13]. This observation has provided one of the major rationales for developing radiolabeled monoclonal antibodies as part of the preparative regimen (see below).
Etoposide (VP16) has also been given with fractionated TBI at a maximally tolerated dose of 60 mg/kg [15], with excellent results having been obtained in large numbers of patients [16,17]. In addition, VP 16 has been combined with cyclophosphamide and TBI (TBI/CY/VP16) in both the autologous and allogeneic setting, in an attempt to reduce relapse rates in patients with high risk or advanced stage hematologic malignancies [18-20].
High dose cytarabine (cytosine arabinoside, usually at a dose of 3 g every 12 hours for six days) also has been given with TBI, with and without cyclophosphamide, in patients with acute leukemia [21,22]. The rationale for this approach is to reduce the likelihood of relapse via the antileukemic activity of cytarabine. However, the possibility superiority of using cytarabine rather than cyclophosphamide remains unproven [23].
The major limitations of fractionated TBI include mucositis, lung toxicity, infertility, and the relatively sophisticated instrumentation required to effectively administer this treatment. In addition, fractionated TBI has been relatively difficult to standardize in multi-institutional trials.
Chemotherapy without radiation — A number of regimens have been developed in which TBI is replaced with additional chemotherapeutic agents (show table 3) [24]. These approaches have primarily been developed for autologous transplantation, but they have also been used in the allogeneic setting. The primary advantage of regimens that lack TBI is reduced toxicity. In addition, the cost is lower, the regimen is easier to administer, and radiation can still be given to sites of prior disease following the transplant [25].
Drug combinations have been selected based upon the biologic activity of the particular drug, the ability to escalate the dose of the drug, and nonoverlapping toxicities when delivering the drugs at their maximally tolerated dosages. The most widely used non-radiation-containing regimen is the combination of busulfan and cyclophosphamide (Bu/Cy) [2,26-31].
The efficacy of busulfan appears to be influenced by the pharmacokinetics in each individual. In one series of 45 patients with chronic myelogenous leukemia, the steady state serum drug concentrations achieved after the oral administration of busulfan varied widely (642 to 1749 ng/mL) following the standard dose of 16 mg/kg [32]. Patients who achieved drug levels below the median had an increased rate of relapse compared to those with values above the median (32 versus zero percent). An intravenous formulation of busulfan, which may reduce this variability, is now approved and is in routine clinical use [33].
Other non-radiation-containing regimens that have been successful include busulfan and etoposide in patients with acute myelogenous leukemia [14,34,35], and cyclophosphamide, carmustine (BCNU), and etoposide, which is widely used in patients with Hodgkin's and non-Hodgkin's lymphomas [36-38]. Different doses and schedules of these drugs have been employed at various transplant centers, making it difficult to compare results with this regimen from one study to the next.
A significant problem with carmustine-containing regimens has been the relatively high incidence of pulmonary fibrosis, particularly in patients who have received prior radiotherapy to the chest [39,40]. This condition may respond to corticosteroids (approximate prednisone dose 1 mg/kg) in early disease. (See "Nitrosourea (carmustine)-induced pulmonary injury"). In an attempt to minimize this risk, lomustine (CCNU) has been used in place of carmustine in patients at high risk for lung toxicity, with encouraging results [41].
Another approach to minimizing lung toxicity is the combination of busulfan, melphalan, and thiotepa, followed by autologous peripheral blood progenitor cells in patients with aggressive or relapsed lymphoma [42]. Among the 40 patients treated with this regimen, interstitial pneumonitis developed in only one patient who had received prior lung radiotherapy.
The preparative regimen also may vary with the nature of the underlying disease. Among patients with aplastic anemia, for example, it is desirable to increase the degree of immunosuppression (to prevent rejection of the graft) while avoiding excessive myelotoxicity. This has been successfully achieved with the combination of cyclophosphamide and antithymocyte globulin [43]. (See "Hematopoietic cell transplantation in aplastic anemia").
High dose combination chemotherapy with autologous bone marrow support has been given to patients with metastatic and high-risk breast cancer. Two regimens that have been employed in large numbers of patients are cyclophosphamide, thiotepa, and carboplatin, and cyclophosphamide, cisplatin, and carmustine [39,44,45]. The efficacy of this approach remains unproven and controlled trials are in progress [46].
Comparison of Bu/Cy with TBI/Cy — It is difficult to compare the relative efficacy of the large number of different regimens which have been developed, since there are few direct comparisons in randomized clinical trials. In addition, it is likely that patient selection has a large impact on the results obtained, making it difficult to assess the impact of any given preparative regimen from the large number of phase II trials reported in the literature. However, a number of retrospective and randomized trials, including one meta-analysis, have compared Bu/Cy to TBI/Cy [2,6,27,47]:
The International Bone Marrow Transplant Registry retrospectively compared outcomes following allogeneic HCT in 381 HLA-matched sibling transplants receiving Bu/Cy with 200 transplants using TBI/Cy for acute myeloid leukemia in first remission [47]. The incidence of hepatic veno-occlusive disease (VOD) was higher with Bu/Cy than with TBI/Cy (13 versus 6 percent, p = 0.009) and the relapse risk was higher with Bu/Cy (relative risk 1.7, 95 percent confidence interval: 1.05 to 2.81). Nevertheless, there were no differences in treatment-related mortality, risk for acute or chronic graft-versus-host disease, leukemia-free survival, or overall survival between the two treatments.
A meta-analysis of five prospective randomized studies comparing Bu/Cy with TBI/Cy came to similar conclusions [6], with an increased risk of hepatic VOD in the Bu/Cy group (odds ratio 2.5, 95% CI: 1.2-5.2) but no significant differences in acute or chronic GVHD, interstitial pneumonitis, disease-free survival, or overall survival.
However, these studies did not include dose adjustment of busulfan based upon pharmacokinetics, which may have an impact on regimen- related complications, such as hepatic VOD. (See "Pathogenesis and clinical features of hepatic veno-occlusive disease following hematopoietic cell transplantation", section on Conditioning therapy and drug toxicity).
MULTIPLE CYCLES OF HIGH DOSE CHEMOTHERAPY — A major advance in the field of transplantation has been the introduction of mobilized peripheral blood progenitor cells (PBPCs) as the source of hematopoietic stem cells. The rapidity of engraftment correlates with the dose of CD34+ cells, such that more than 2 x 10(6) CD34+ cells/kg are required for rapid neutrophil recovery, while more than 5 x 10(6)/kg can hasten platelet recovery and may be preferred in patients with prolonged pretransplant chemotherapy exposure [48,49]. (See "Sources of hematopoietic stem cells").
In many patients, collection of stem cell doses far exceeding these thresholds can be readily achieved. This permits an approach consisting of multiple cycles of high dose chemotherapy followed by the infusion of PBPCs after each cycle, in an attempt to increase the intensity of anticancer therapy beyond that achievable with a standard autologous transplant. Each cycle is at or near myeloablative levels of chemotherapy, followed by rescue with previously collected PBPCs.
A variety of diseases have been treated in this fashion in pilot studies, including metastatic breast cancer, Hodgkin's disease, and non-Hodgkin's lymphomas; impressive response rates have been achieved [50-52]. Many of these regimens have been administered on an outpatient basis with pulmonary and gastrointestinal toxicities being the major limiting factors. At present, there is little evidence that this approach increases the long-term disease free survival rate over that achieved with a standard transplant [45,53].
However, this is an important experimental model, since it gets to the heart of the potential role of transplantation in the treatment of malignant disease, and attempts to assess whether peak dose or dose intensity (ie, total dose) is the more important effect. If additional trials confirm a lack of advantage from the use of multiple cycles of chemotherapy followed by PBPCs, this would argue that the peak dose is the most important consideration in achieving clinical benefit.
RADIOLABELED MONOCLONAL ANTIBODIES — As mentioned above, the maximally tolerated dose of TBI is approximately 15 Gy. Randomized trials comparing 12 and 16 Gy found that the higher dose was associated with a lower relapse rate (eg, 12 versus 35 percent at three years in patients with acute myeloid leukemia), but no improvement in overall survival due to a higher rate of complications [13,14]. These observations suggest that improvements in disease-free survival might be attained if the radiation dose could be increased without excessive toxicity.
One approach to achieving this goal has been the administration of monoclonal antibodies radiolabeled with high energy emitting radioisotope. This would permit targeting of the radiation dose to the tumor cells and marrow with potential reduction in dose to other organs, such as the liver, lungs and kidneys. One such monoclonal antibody is directed against CD45, which is highly expressed on hematopoietic cells, thereby allowing targeting to the marrow space [54,55]. In one report, 34 patients with advanced acute leukemia or myelodysplastic syndrome were treated with an iodine-131 conjugated CD45 monoclonal antibody, which resulted in an estimated marrow dose of 40 to 300 Gy, followed by conventional doses of fractionated TBI(12 Gy)/Cy and autologous or HLA-matched related allogeneic transplantation [55]. Toxicity was no greater than expected and response rates were excellent. Among 25 treated patients with acute myeloid leukemia or myelodysplastic syndrome, seven are alive and disease-free at a median of 65 months after transplantation.
A variety of other monoclonal antibodies and radioisotopes are likely to be tested in the future. This approach raises the possibility of directing the preparative regimen to sites of disease, thereby sparing normal tissues. One concern is that high doses of radioactivity delivered to the marrow space may injure or kill stromal cells. In addition, the delivery of such high doses of radioisotopes requires sophisticated expertise, equipment, and shielding of the patient to avoid risk to health care workers.
NONMYELOABLATIVE PREPARATIVE REGIMENS — Among patients with leukemia treated with allogeneic HCT, an important contributing factor is a graft-versus-tumor (GVT) effect mediated by donor immunocompetent cells [56]. The importance of GVT is illustrated by the different outcomes with grafts from identical twin and nonidentical donors. Patients who have an identical twin donor do not develop GVHD, but are at higher risk of relapse of the underlying malignant disease than similar patients transplanted with HLA-matched but nonidentical sibling donors.
These relationships were illustrated in a review from 163 transplant centers which compared the results of 103 identical twin (syngeneic) and 1030 HLA-identical sibling (allogeneic) transplants for various forms of acute or chronic leukemia [57]. The three-year probability of relapse of leukemia was substantially higher in the syngeneic than in the allogeneic transplants in acute myelocytic leukemia (52 versus 16 percent) and chronic myelocytic leukemia (40 versus 7 percent). Survival was similar with the two types of transplants because the increased incidence of leukemia relapse with identical twin transplants was counterbalanced by less treatment-related mortality. (See "Biology of the graft-versus-tumor effect following hematopoietic cell transplantation").
The GVT effect requires the engraftment of donor type immunocompetent cells, which does not necessarily require a toxic myeloablative preparative regimen (show figure 1). As a result, the possibility of achieving mixed hematopoietic chimerism, defined as the concurrent presence of donor and recipient hematopoietic cells, using nonmyeloablative regimens ("minitransplants") has been extensively explored [58-63].
This approach, which relies more on donor cellular immune effects and less on the cytotoxic effects of the preparative regimen to control the underlying disease [56,64,65], permits transplantation in older, as well as high-risk, heavily pretreated patients, with an attendant decrease in regimen-related toxicity and treatment-related mortality [66-72]. Three salient observations are the underpinnings of these nonmyeloablative approaches [60]:
In many instances, cancer cells cannot be eradicated entirely by high dose chemotherapy alone (eg, multiple myeloma, see "Hematopoietic cell transplantation in multiple myeloma", section on Allogeneic bone marrow transplantation), or patients with these disorders are too ill because of age and/or co-morbidities to tolerate myeloablative chemotherapy followed by transplantation [67,73,74].
Many observed long-term tumor responses have been brought about by immunologic antitumor effects (ie, graft-versus-tumor effect) generated by the allograft (eg, donor lymphocyte infusion in CML relapsing after allogeneic HCT, see "Hematopoietic cell transplantation in chronic myelogenous leukemia", section on Nonmyeloablative transplantation) [56,75].
For many genetic disorders, a state of mixed donor-host chimerism is sufficient to relieve the patient of disease-related manifestations (eg, beta thalassemia major, see "Specific issues related to hematopoietic cell transplantation in beta thalassemia", section on Mixed chimeric state).
The following examples are illustrative of the wide range of non-randomized clinical trials using this concept, involving patients with a variety of hematologic and oncologic malignancies or genetic disorders:
Eighty-nine patients with a variety of underlying hematologic malignancies, either >50 years of age or <50 class="see" onclick="javascript:return viewDrugTopic('topic.do?topicKey=drug_a_k/106308&drug=true');" href="http://www.uptodateonline.com/utd/content/topic.do?topicKey=drug_a_k/106308&drug=true">fludarabine (90 mg/m2) and 2 Gy total body irradiation, followed by hematopoietic cell transplantation from HLA-matched unrelated donors [76]. The cumulative probability of grades III-IV acute GVHD was 10 percent, with a 100 day non-relapse mortality of 11 percent and one-year overall survival of 52 percent.
Twelve patients with heavily pretreated, refractory hematologic malignancies were given total body irradiation (1 Gy) followed by infusion of nonmobilized allogeneic peripheral blood cells without GVHD prophylaxis [77]. Four patients had complete remission; tumor response correlated with donor chimerism and previous myelotoxic chemotherapy, suggesting that the degree of prior immunosuppression may have been a determinant of engraftment [63].
A number of studies performed in patients with metastatic renal cell carcinoma and other solid tumors have shown clinical responses and evidence for a graft-versus-tumor effect after use of nonmyeloablative allogeneic HCT with or without subsequent donor lymphocyte infusion [56,64,78,79]. (See "Immunotherapy of renal cell carcinoma", section on Nonmyeloablative allogeneic peripheral-blood stem cell transplantation).
In the light of reduced intensity of conditioning regimens, and with the induction of partial chimerism, donor leukocyte infusions [80] or other immunotherapeutic interventions could be applied in an effort to balance the interactions between the following competing issues (see "Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation") [81-89]:
Maximizing the graft-versus-tumor effect (show figure 1)
Minimizing acute and chronic graft versus host disease (GVHD)
Minimizing graft rejection
Minimizing opportunistic infections (eg, CMV infection) through rapid immune reconstitution [90]
This approach relies heavily on the serial assessment of chimerism, using techniques such as fluorescence in situ hybridization (FISH) or analysis of a variable number of tandem repeats (VNTR) between donor and recipient [91-95]. (See "Cytogenetic and molecular genetic diagnostic tools", section on Fluorescence in situ hybridization).
Clearly, much needs to be done to determine the relative role of this transplant approach, including such variables as the age and overall comorbidity status of the recipient, the degree of HLA matching of the donor, and the agents and doses used in the reduced intensity conditioning regimens and GVHD prophylaxis [96-98].
OTHER EXPLOITATION OF THE GRAFT VERSUS TUMOR EFFECT — A similar exploitation of the graft-versus-tumor effect may be obtained by omitting immunosuppressive treatment following allo-HCT until clinical evidence of graft-versus-host disease is observed. In a study of patients with high-risk hematologic disease (eg, chemoresistant relapse, primary refractory disease), all 12 patients developed grade III-IV acute GVHD, and seven of nine evaluable patients developed chronic GVHD. Six are alive 5 to 26 months post-HCT, five of whom are in complete remission [99]. This highly risky strategy should only be used in the context of a clinical trial aimed at assessing whether this is an effective approach in high-risk patients.
INFORMATION FOR PATIENTS — Educational materials on this topic are available for patients. (See "Patient information: Overview of bone marrow transplantation"). We encourage you to print or e-mail this topic review, or to refer patients to our public web site, www.patients.uptodate.com, which includes this and other topics.

Donor selection for hematopoietic cell transplantation

INTRODUCTION — The selection of a donor for a hematopoietic cell transplant procedure is a critical element which contributes to the overall success of the transplant. There are several possible sources for these cells:
An identical twin (syngeneic)
A sibling or unrelated donor (allogeneic)
The patient himself or herself (autologous)
Umbilical cord blood as a source of hematopoietic stem cells.
The decision as to which donor source to utilize depends to a large degree upon the clinical situation and the approaches employed at the individual transplant center. (See "Sources of hematopoietic stem cells"). This topic review will provide an overview of the general issues involved in donor selection for hematopoietic cell transplantation.
GENERAL CONSIDERATIONS — Transplant donors must be in generally good health without other comorbid conditions. The donor must have a performance status that will permit the safe collection of the cells, either by bone marrow (BM) or peripheral blood progenitor cell (PBPC) collection [1]. (See "Sources of hematopoietic stem cells"). Thus, the donor must be able to tolerate anesthesia (either general or regional) and have adequate cardiac, pulmonary, hepatic and renal function. Pediatric donors are only utilized for autologous collection or donation to siblings. Donors with ongoing malignancies or a history of a malignant condition other than minor skin cancers (eg, basal cell carcinomas) are generally excluded from further consideration.
Viral serologic studies are performed on all donors, who must be negative for both anti-HIV antibodies and HIV RNA. (See "Serologic tests for the diagnosis of HIV infection"). Serologic tests for hepatitis B and C are also required at most transplant centers. Donors with active viral hepatitis are usually excluded although exceptions are occasionally made with sibling donors, depending upon the clinical urgency [2]. In certain circumstances, antiviral therapy may be considered if time permits for an adequate course [3].
The following additional studies are routinely performed on hematopoietic cell donors:
History and physical examination, including a careful history of past bleeding events and allergies
Past surgical and obstetrical history
Complete blood count with platelet count
Serum creatinine and electrolytes and liver function studies
Serologic studies for cytomegalovirus (CMV) and herpes viruses
ABO blood typing
Chest x-ray
Electrocardiogram
Effect of donor age and other characteristics — The National Marrow Donor Program has completed a retrospective analysis of 6,978 unrelated bone marrow transplants performed from 1987 to 1999 in order to study the effects of various donor characteristics (eg, age, sex, CMV serologic status, ABO compatibility, race, and parity) on recipient outcome [4]. Mobilized peripheral blood transplants were excluded from this analysis. The following major findings were reported:
Age was the only donor trait significantly associated with overall and disease-free survival. Five-year overall survival rates were 33, 29, and 25 percent for donors aged 18 to 30, 31 to 45, and >45 years, respectively. A similar effect was observed among HLA-mismatched cases.
The cumulative incidence of grade III or IV acute graft versus host disease (GVHD) were 30, 34, and 34 percent for donors aged 18 to 30, 31 to 45, and >45 years, respectively (p = 0.005). The corresponding incidences of chronic GVHD at two years were 44, 48, and 49 percent, respectively (p = 0.02).
Recipients with female donors who had undergone multiple pregnancies had a higher rate of chronic GVHD (54 percent) than recipients with male donors (44 percent, p<0.0001).
Other studies have found that younger donors are associated with lower incidences of secondary graft failure [5], B-cell lymphoproliferative disorders [6], and obstructive lung disease [7] following allogeneic transplantation.
IDENTICAL TWIN DONORS — Rarely, patients who are candidates for hematopoietic cell transplantation have an identical twin who can serve as the donor. These patients do not require posttransplant immunosuppression and do not develop graft-versus-host disease (GVHD). However, they are at a higher risk of relapse of the underlying malignant disease than similar patients transplanted with HLA-matched but nonidentical sibling donors [8]. This is especially true for patients transplanted for acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML), less so for patients with acute lymphoblastic leukemia (ALL) [9], and has not been demonstrated in patients transplanted for non-Hodgkin's lymphoma [10].
These relationships were illustrated in a review from 163 transplant centers which compared the results of 103 identical twin (syngeneic) and 1030 HLA-identical sibling (allogeneic) transplants for leukemia [9]. The three-year probability of relapse of leukemia was substantially higher in the syngeneic than allogeneic transplants in AML (52 versus 16 percent) and CML (40 versus 7 percent); the GVL effect was less apparent and not statistically significant in ALL (36 versus 26 percent).
The reason for this apparent disparity is uncertain but is presumably related to the ability of the donor lymphocytes to recognize the recipient tumor cells, ie, a graft-versus-leukemia (GVL) reaction [11]. Interestingly, survival was similar with the two types of transplants because the increased incidence of leukemia relapse with identical twin transplants was counterbalanced by less treatment-related mortality.
Molecular scrutiny of the blood of the healthy twin (and potential transplant donor) is particularly relevant if the malignant clone in the unhealthy twin may have been present in utero, as has been shown for acute leukemia [12,13]. Under such circumstances, identical twins with a shared placental circulation may be harboring the identical malignant clone, with one twin developing clinically evident leukemia in advance of the other.
MATCHED RELATED DONORS — Related donors are generally siblings since they have the opportunity to inherit the same human leukocyte antigen (HLA) genes located on chromosome 6. There is a 25 percent chance that a given sibling will be HLA-matched at the A, B, and DR loci which are the principal loci evaluated using serologic methods. (See "HLA: A roadmap"). In matched siblings, serologic typing is adequate, since a match at these loci makes it highly likely that the same genes were inherited from the parents.
HLA-matched sibling donors are generally the preferred donor source for an allogeneic transplant. It is unlikely that matched related donors will be anything other than siblings unless the parents happen to have very common haplotypes or there has been intermarrying among families, such that first cousins might be fully HLA-matched.
MISMATCHED RELATED DONORS — In most centers, a complete match at the HLA-A, -B and -DR loci is required for that individual to be used as a transplant donor. In some cases, siblings are mismatched at a single HLA locus. Transplants from single antigen mismatched siblings are associated with a higher risk of GVHD, although overall survival may not be different from that observed with fully matched siblings [14,15]. Thus, the use of one antigen mismatched siblings is considered in some centers, depending upon the clinical situation (eg, high- versus standard-risk patient, amount of time available for a matched unrelated donor search) [15].
Haploidentical donors — Other transplant centers are exploring the use of donors who are only haploidentical and therefore mismatched at three loci [16]. Although encouraging data have been obtained, this approach is only being explored at centers with expertise in this area [17-19]. In one series of 72 such patients, engraftment at 30 days occurred in 88 percent, grade II to IV acute GVHD in 16 percent, and severe chronic GVHD in 8 percent of evaluable patients [18]. Disease status at the time of transplant was the only factor significantly predictive of outcome. The authors concluded that, in patients who will be treated with an allogeneic transplant, progression of the underlying disease can be avoided by using a haploidentical donor.
Another study evaluated the efficacy of haploidentical transplantation with T-cell depleted stem cells in 43 patients with high-risk acute leukemia [20]. Remarkably, full engraftment was achieved in all patients and none of the evaluable patients developed acute or chronic GVHD. Relapse of the underlying disease occurred mainly in patients with acute lymphoblastic leukemia, especially those who were transplanted with advanced disease. Infection was a significant problem which was thought to be due to the slow recovery of T cell immunity. Attempts are ongoing to avoid this problem through adoptive immunotherapy, by adding allodepleted donor T-cells [21].
A novel approach to inducing graft-versus-leukemia (GVL) activity has been identified, namely GVL mediated by donor-derived natural killer (NK) cells. In haploidentical transplants, donor and recipients differ at multiple HLA class I loci, and NK cell-mediated cytotoxicity is to a large extent governed by appropriate MHC class I expression. Thus, NK cells from a haploidentical donor could recognize the recipient as foreign and be alloreactive. In one study, presence of alloreactive NK cells was demonstrated only in those clinical settings predicted by HLA typing [22]. (See "Biology of the graft-versus-tumor effect following hematopoietic cell transplantation", section on Natural killer cells).
In both clinical transplantation studies and mouse modeling, alloreactive NK cells can protect recipients from myeloid (but not lymphoid) leukemia, graft rejection, and GVHD, possibly through destruction of recipient dendritic cells [23]. These observations raise the possibility of selecting donors for NK cell alloreactivity, since, in the haploidentical setting, most patients have a number of possible donors (see below).
A lower risk of developing GVHD with haploidentical donors may result from the ex vivo treatment of donor bone marrow cells with irradiated recipient cells and CTLA-4-Ig (abatacept), an agent which can help render donor T cells anergic to host cells because of the blockade of costimulatory signals. (See "MHC structure and function"). In one study of 12 patients with amegakaryocytic thrombocytopenia, or persistent lymphoma or leukemia, marrow cells from haploidentical donors were incubated for 36 hours with irradiated recipient peripheral mononuclear cells and abatacept [24]. After myeloablation and immunotherapy, treated donor cells were infused into the recipient [24]. Although four patients had GVHD (one with chronic and three with acute disease confined to the gastrointestinal tract), no deaths occurred secondary to GVHD and five patients were in remission 5 to 29 months after HCT.
Maternal versus paternal antigens — Mismatching of maternal, rather than paternal, antigens seems to be better tolerated in haploidentical transplants, presumably due to exposure to maternal HLA antigens during the prenatal and perinatal period [25]. There is evidence that males and nulliparous females are preferred over parous female donors, since the risk of GVHD has been slightly higher in some studies in the latter group [26]. This may be due, in part, to pregnancy- associated alloimmune responses against paternal minor H antigens [27].
This effect was evaluated in a study of 269 subjects receiving one or two antigen-mismatched sibling or parental non-T-cell depleted transplants, using data from the International Bone Marrow Transplant Registry [28]. Results included the following:
Sibling transplants mismatched for paternal antigens had similar rates of transplant-related mortality (TRM) and graft failure, but higher rates of acute GVHD than maternal-mismatched transplants (relative risk (RR): 1.86, 95 percent confidence interval (CI): 1.15 to 3.05).
In the first four months post-transplant, father-to-child transplants involved significantly more chronic GVHD than mother-to-child transplants (RR: 2.44, 95% CI: 1.12-5.34).
When compared with maternal-mismatched sibling transplants, a transplant from either parent was equally likely to be associated with an increase in treatment-related mortality (RR: 2 for each).
Multiple potential donors — One potential advantage of using haploidentical donors is that within a given family there are usually multiple individuals who could serve as potential donors including parents, siblings, and children [29]. As a result, the donor used could be chosen depending upon HLA type, CMV status, blood type, or other features which could have potential clinical implications [30-33]. Another advantage is equal availability of donors for all ethnic and racial groups in contrast to matched unrelated donors (see below).
CMV status — Sibling donors must be in generally good health as discussed above and be serologically negative for viral infection, especially HIV. In the unusual situation in which there is more than one sibling donor, CMV status is usually used to decide which donor to utilize especially if the recipient is CMV seronegative. In this setting, a CMV seronegative donor is preferred since this will greatly reduce the risk of subsequent infection with CMV, assuming that the patient receives CMV seronegative blood products.
ABO and Rh status — ABO and Rh compatibility are not required between the donor and recipient. Hemolysis, delayed erythropoietic engraftment, and pure red cell aplasia (PRCA) may complicate ABO-incompatible transplantation after either marrow or PBSC transplantation, but are not common [34-39]. Similarly, anti-D seldom develops in RhD-mismatched recipients of a myeloablative allogeneic hematopoietic cell transplantation, but may occur following non-myeloablative conditioning [40,41]. Data from two studies suggest that major ABO-incompatibility is not a barrier to successful non-myeloablative transplantation [42,43], although transplant-related morbidity and mortality were higher in a third study [44].
If, however, major mismatches are present, additional manipulation of the hematopoietic cell product, such as depleting the product of red cells or plasma prior to infusion, may [45] or may not [34] be required. It is not clear whether major or minor ABO mismatches are associated with a higher incidence of GVHD and/or reduced overall survival [46-48].
Cases of delayed hemolysis and/or PRCA have been described in patients with pre-existing alloantibodies against Rh or ABO antigens, despite the presence of 100 percent donor chimerism of the circulating lymphocytes [49,50]. This phenomenon, including persistence of other host-derived antibodies post-transplantation, may be due to the presence of long-lived antibody-producing recipient plasma cells surviving the transplantation regimen [50-52]. (See "Acquired pure red cell aplasia").
MATCHED UNRELATED DONORS — In 1986, the National Marrow Donor Program (NMDP) was established as a repository for HLA-typing information so that unrelated donors and recipients could be matched [53]. Many international registries have also formed which allow for the worldwide search for appropriate donors for those in need of a bone marrow transplant procedure [54,55].
At present, there are over four million donors registered in the NMDP data bank, all of whom have undergone HLA-A and -B serologic typing. The number of potential donors is increasing with greater public awareness of the need. A significant percentage have also undergone serologic typing at the C and D region and some have had molecular typing.
It is more difficult to find a donor for patients from certain ethnic and racial backgrounds. As an example, it has been estimated that a matched unrelated graft has been made available for 50 percent of Caucasians compared to less than 10 percent of minorities in need in the United States [18]. This is part due to underrepresentation in the data bank; in addition, African-Americans and Asian-Americans are more polymorphic than Caucasians with respect to HLA and have a relatively large number of haplotypes that are specific to their racial groups, making it more difficult to find donors at any registry size [56,57].
Serologic versus molecular typing — Since the donor and recipient are not related, serologic typing alone does not ensure that those individuals share the same HLA genes. This is evident clinically by the higher risk of GVHD in recipients of unrelated donor grafts [58]. DNA-based techniques have been developed which permit molecular typing, which has demonstrated that only about 55 percent of serologically identical donor and recipient pairs (ie, antigen matched) are highly matched by molecular typing (ie, allele matched) [59-63]. Patients who are truly highly matched appear to have better outcomes:
In one series of 44 unrelated patient-donor pairs who were serologically matched, the 24 patients who were highly matched by molecular techniques had a 21 percent incidence of severe GVHD compared to 47 percent in those who were not highly matched [59]. Other significant advantages in the highly matched patients were a lower transplant-related mortality (21 versus 57 percent) and a higher three year actuarial survival (61 versus 13 percent).
In a second report, molecular DNA typing was performed in 440 recipients transplanted from unrelated donors who were serologically identical with their donors for HL-A, B, and DR antigens [60]. When DNA-based genotyping was performed, only 55 percent were identical at the tested HLA-A, B, and DR alleles and 69 percent were identical at the HLA-C alleles which were not tested serologically. HLA-DP matching was present in less than 50 percent but did not appear to affect the outcome. Multivariate analysis showed that mismatching at the HLA-A allele was an independent risk factor for severe GVHD and death (show figure 1), and that mismatching at the HLA-C allele was an independent risk factor for severe GVHD and for a lower rate of recurrence of leukemia in those transplanted for that disease (show figure 2). The importance of class C mismatching has been noted in another series in which patients who had an HLA-C disparity had a relative risk for graft failure of 4.0 after accounting for the contribution HLA-A and HLA-B mismatches [62].
In a study of 1874 donor-recipient pairs retrospectively typed at both low and high resolution, mismatches at HLA-A, -B, -C, and -DR1 each had similar adverse effects on mortality, while only HLA-A mismatches demonstrated significant effects on GVHD [64]. Adverse effects on outcome were more evident in transplants with low-resolution (ie, antigenic) versus only high-resolution (ie, allelic or molecular) mismatches. Of importance, mismatching at the HLA-DQ or -DP loci did not significantly affect outcome.
The question of which mismatches are tolerated and which result in adverse clinical outcomes continues to be actively investigated. Most transplant centers now require complete serologic and molecular matching at the class II region to use that donor for a given transplant procedure. However, as noted above with siblings, the degree of HLA disparity which is tolerable depends upon many factors, including the clinical situation of the recipient [65].
Use of these various advances has resulted in continued improvement in the outcome of patients transplanted with bone marrow obtained from unrelated donors [66,67]. Reducing the degree of mismatch with sophisticated genotyping has, as noted above, resulted in decreased mortality following unrelated bone marrow transplants [59,60,68]. However, requiring more specific testing will undoubtedly reduce the number of donors available for an individual patient and may increase the amount of time required to locate a match, since the vast majority of patients in the registries have been typed with serologic assays.
Time is an issue even with serologic typing as it may take up to six months to complete a search for a matched unrelated donor. This is largely due to the lack of complete typing data for the entire donor population and the large expense required to perform all of the typing tests on all possible donors. In one study of 240 patients of Dutch origin, for example, an appropriate donor could be identified in approximately 70 percent of cases [69]. The search required six months. Approximately one-third of patients were transplanted, one-third had a potential donor but did not receive the transplant, and one-third did not have a suitable donor.
The long search times make this approach feasible only for those diseases with suitable clinical courses. This includes chronic myelogenous leukemia (CML), myelodysplastic syndromes, and aplastic anemia, and when searches are initiated early in the course of treatment of patients with high-risk leukemias. (See appropriate topic reviews).
Once an appropriate donor is identified through the registry, the donor must be screened as discussed above for general health and suitability. The bone marrow is harvested locally and then transported to the transplant center. It is feasible to collect donor hematopoietic cells virtually anywhere in the world.
Due to the higher risk of GVHD in recipients of matched unrelated donor transplants [57], T-cell depletion techniques have been employed in an attempt to reduce this complication:
One approach is to utilize anti-thymocyte globulin (ATG) [67]. In one study, fifty-five adults with AML, CML, or MDS received matched unrelated transplants with GVHD prophylaxis including ATG, cyclosporine, and methotrexate [70]. The incidence of acute GVHD (grade II-IV) was 15 percent, which appears favorable. Chronic GVHD occurred in 51 percent of the patients; graft failure did not occur. The cumulative incidence of relapse within one year was zero. All 14 patients with CML became bcr-abl negative within 250 days.
A national trial is underway comparing the outcomes of patients who undergo T-cell depletion using the B10T9 monoclonal antibody as compared to those patients who undergo a conventional T-cell replete transplant.
Predictors of engraftment and survival — The results in 5,246 patients who underwent unrelated donor bone marrow transplantation facilitated by the National Marrow Donor Program between August, 1991 and June, 1999 have been reported [5]. The following donor and recipient factors were significantly associated with successful engraftment:
Hematopoietic cells matched at HLA-A, HLA-B, and DRB1
Higher cell dose
Younger recipient
Male recipient
Recipient from a non-African American ethnic group
CMV status — In the above study, recipient seronegativity for CMV was associated with more rapid myeloid and platelet engraftment; other studies have also shown a lower risk of treatment-related mortality and improved survival for CMV seronegative recipients transplanted with seronegative donors [71-73].
However, a CMV seropositive donor may be preferred when the recipient is CMV seropositive. A retrospective EBMT study indicated significantly better event-free survival (30 versus 22 percent), five-year overall survival (35 versus 27 percent), and transplant-related mortality (49 versus 62 percent) when CMV seropositive patients received CMV seropositive, rather than seronegative unrelated donor transplants [74]. This benefit was abrogated by T-cell depletion, suggesting that the effect was mediated through transfer of donor immunity.
Umbilical cord blood donors — Relatively high numbers of hematopoietic stem cells are present in umbilical cord blood collected at the time of delivery. These cells can be processed and cryopreserved in cord blood banks. (See "Sources of hematopoietic stem cells"). Following HLA-matching to a recipient, the cord blood unit can be transported to the transplant center with minimal delay and used.
Due to the relative immaturity of the immune system in cord samples, stem cells from this source allow the crossing of immunologic barriers that would otherwise be prohibitive. As a result, the degree of HLA-disparity which is tolerable is much greater. In one series of 25 children (24 of whom were discordant for one to three HLA antigens), cord blood stem cell transplantation was associated with engraftment in 23 and with acute severe GVHD in only 2 of 21 evaluable cases [75].
A major advantage of the use of cord blood is that the cells are already collected and cryopreserved, which greatly reduces the time required for accessing the donor and completing the transplant procedure [76]. In addition, the degree of mismatching tolerated with cord blood transplantation may make this approach more feasible for members of minorities that are underrepresented in volunteer donor registries. (See "Collection and storage of umbilical cord blood for hematopoietic cell transplantation").
Efficacy — Engraftment occurs after infusion of cord blood products, although it may be delayed in some instances depending upon the number of cells and size of the recipient. One report evaluated 562 recipients who were usually matched for at least five of six of the unrelated placental blood donor's HLA-A, -B, and -DR antigens [77]. The median time to engraftment was 28 days for neutrophils and 90 days for platelets; 81 percent were engrafted for neutrophils by day 42 and 85 percent of platelets by day 180.
Long-term survival has been accomplished, depending upon the source of the cord blood and the nature of the underlying disease [77,78].
In one review of 78 recipients of cord blood from related donors, estimated one year survival was 63 percent; GVHD of at least grade II occurred in 9 percent of HLA-matched recipients and 50 percent of HLA-mismatched recipients [78]. The results were not as good in 65 patients who received cord blood from unrelated donors: estimated one year survival was only 29 percent.
Somewhat better results with unrelated cord blood donors were noted in the above series of 562 patients: severe acute GVHD occurred in 23 percent and chronic GVHD in 25 percent [77].
Limitations — A major limitation is the relatively small volume of the cord blood collections which makes it difficult to use this approach for transplantation in larger adults. The possibility of expanding the cord blood stem cells in vitro is an area of active investigation.
Another potential problem is the possibility of bacterial contamination in cord blood collections which could complicate the transplant procedure. In one careful evaluation of cord blood collection and processing practices, bacterial contamination occurred in 18 percent of collections, a level which could be reduced to below 1 percent with practical experience [79]. Cord blood was associated with a low risk of CMV positivity (0.3 percent of samples). Thus, the likelihood of developing CMV infection following a cord blood transplant is primarily related to the recipient status. Among 500 recipients with known CMV status, the incidence of CMV infection was 23 percent in seropositive recipients and 3 percent in seronegative recipients [77].
Initiating the search — To initiate a preliminary search of the National Marrow Donor Program (NMDP), contact the NMDP Office of Patient Advocacy at the following toll-free telephone number:1-888-999-6743. Alternatively, a preliminary search request form can be submitted through the NMDP website at www.marrow.org [80].
INFORMATION FOR PATIENTS — Educational materials on this topic are available for patients. (See "Patient information: Overview of bone marrow transplantation"). We encourage you to print or e-mail this topic review, or to refer patients to our public web site, www.patients.uptodate.com, which includes this and other topics.
OVERALL APPROACH AND CONCLUSIONS — At present, there are multiple options available in selecting a donor and stem cell source. (See "Sources of hematopoietic stem cells"). As a result, firm recommendations cannot be made. The clinical problem, overall health of the donor and recipient, infectious history, clinical approach of the transplant center, and other factors are important in deciding what type of donor is selected.
Most transplant centers prefer an identical twin donor in those rare instances when one is available and, in other patients, an HLA-matched sibling donor for allogeneic transplantation when one is available [58]. If an HLA-matched sibling donor is not available, then searching the bone marrow registry for unrelated matched donors is the next most suitable option [81]. The roles of cord blood donors and mismatched related donors are areas of ongoing clinical investigation in which results are continuing to improve [82,83]. With all of these approaches, donor safety is of paramount importance and careful screening is imperative to avoid unforeseen complications

New in hematology

ACUTE LYMPHOBLASTIC LEUKEMIA
In a study of 29 older adults with Philadelphia chromosome-positive acute lymphoblastic leukemia, the combination of imatinib and prednisone resulted in a complete response rate of 100 percent, a median duration of response of 8 months, and an estimated 12 month disease-free survival of 48 percent [1]. (See "Treatment of acute lymphoblastic leukemia in adults", section on Philadelphia chromosome positive ALL).
ACUTE MYELOID LEUKEMIA
Based on a meta-analysis which included results from randomized HOVON-SAKK, MRC, BGMT, and EORTC studies in more than 4,000 patients with acute myeloid leukemia (AML) in first complete remission, it was concluded that HLA-matched sibling allogeneic hematopoietic cell transplantation should be considered as the treatment of choice in younger adults with intermediate or poor-risk AML in first complete remission [2]. (See "Treatment of acute myeloid leukemia in adults", section on Clinical trials of transplantation efficacy).
ANEMIA IN CANCER PATIENTS
Preliminary results from a phase III randomized, placebo-controlled study of darbepoietin in 989 patients with active cancer and anemia not due to concurrent chemotherapy have shown lack of utility and even harm when darbopoietin is used in this group of patients [3,4]. On February 16, 2007 the United States FDA issued a black box safety alert indicating that treating anemic cancer patients not currently on chemotherapy with an erythropoiesis-stimulating agent (ESA) may offer no benefit and may cause serious harm. (See "Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on Patients not receiving chemotherapy).
ANTICOAGULATION
In a randomized, placebo controlled study in 70 warfarin-treated patients with unexplained unstable control of their INR, dietary supplementation with 150 microg/day of vitamin K significantly improved control of their anticoagulation [5]. (See "Outpatient management of oral anticoagulation", section on Vitamin K supplementation).
CHRONIC LYMPHOCYTIC LEUKEMIA
In an Intergroup phase III trial of fludarabine versus fludarabine plus cyclophosphamide in previously untreated CLL patients, complete remission and overall response rates were not significantly different based on cytogenetics, Vh mutation status, CD38 expression, or p53 mutational status [6]. However, the occurrence of del(17p) or del(11q) was associated with reduced progression-free survival after an initial response, suggesting that patients with these high risk cytogenetic features should be considered for alternative non-fludarabine-based therapy [6]. (See "Staging and prognosis of chronic lymphocytic leukemia", section on Role of CD38, ZAP-70, and Vh gene mutation status and see "Treatment of chronic lymphocytic leukemia", section on High-risk disease).
HIV-ASSOCIATED LYMPHOMA
In a Spanish multicenter study, 62 patients with HIV-associated Hodgkin's disease were treated with six to eight cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) along with HAART (highly active antiretroviral therapy) [7]. The entire treatment course was completed by 83 percent of patients. Eighty-seven percent achieved a complete remission; five-year event-free and overall survival rates were 71 and 76 percent, respectively. (See "Overview of malignancies in HIV infection", section on Hodgkin's disease, subsection on Influence of HAART).
LYMPHOMA GUIDELINES
An international project has been convened to discuss standardization of positron emission tomographic (PET) scanning in lymphoma [8]. (See "Approach to the diagnosis of non-Hodgkin's lymphoma", section on PET scanning.
The International Working Group response criteria for lymphoma have been revised to take into account the increased use of PET scanning, immunohistochemistry, and flow cytometry [9]. (See "Treatment of aggressive non-Hodgkin's lymphoma", section on Response criteria).
MULTIPLE MYELOMA
Based on superior survival as well as lessened toxicity for the lower dose of dexamethasone (dex), as seen in a phase III ECOG trial of lenalidomide plus either high-dose or low-dose dex, the recommended dose of dex when used alone or in combination (eg, dex alone, thalidomide/dex, lenalidomide/dex) in newly diagnosed patients with myeloma has been reduced to 40 mg PO on days 1, 8, 15, and 22 of each 28 day cycle) [10]. (See "Chemotherapy in multiple myeloma", section on Dexamethasone dosing).
A phase I/II trial has shown significant activity for the 4-drug combination of bortezomib, melphalan, prednisone, and thalidomide in 30 patients with relapsed or refractory myeloma [11]. (See "Treatment of relapsed or resistant multiple myeloma", section on Bortezomib, subsection on Initial trials).
In previously untreated as well as relapsed/resistant myeloma, patients with a retinoblastoma gene deletion (ie, chromosome 13q14 deletion) have responded to treatment with bortezomib-containing chemotherapy regimens [12-15]. (See "Treatment of relapsed or resistant multiple myeloma", section on Bortezomib, subsection on High-risk patients).
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
On March 16, 2007, the United States FDA approved eculizumab (Soliris™, Alexion Pharmaceuticals), a monoclonal antibody that binds to the C5 component of complement, for reducing hemolysis in patients with paroxysmal nocturnal hemoglobinuria [16]. Prescribing information for this agent includes a boxed warning describing the risk for serious meningococcal infection and the need for meningococcal vaccination prior to treatment. (See "Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria", section on Eculizumab).
POLYCYTHEMIA VERA
With the discovery of exon 12 mutations of the JAK2 gene in 10 of 11 patients diagnosed as having polycythemia vera (PV) who had tested negative for the exon 14 V617F JAK2 mutation, it appears that virtually all patients with PV have one or the other JAK2 mutations [17]. (See "Diagnostic approach to the patient with suspected polycythemia vera", section on JAK2 mutations).
VENOUS THROMBOEMBOLISM
In a follow-up report from the first International Breast Cancer Intervention Study (IBIS-I), the risk of developing deep vein thrombosis or pulmonary embolus was significantly higher in the tamoxifen arm than in the placebo arm during the five years of active treatment (RR 2.3, 95% CI 1.4-3.9), but not after tamoxifen was stopped (RR 1.1, 95% CI 0.5-2.5) [18]. (See "Drug-induced thrombosis and vascular disease in patients with malignancy", section on Tamoxifen and raloxifene).
On May 1, 2007 the United States FDA approved the use of the low molecular weight heparin dalteparin to reduce the recurrence of symptomatic venous thromboembolism in patients with cancer [19]. (See "Hypercoagulable disorders associated with malignancy", section on Treatment of idiopathic venous thrombosis, subsection on Recommendations).
Based on the results of three well conducted studies, there is no clinical rationale for measurement of plasma homocysteine levels or for assaying for presence of the MTHFR 677C—>T variant when screening for the risk of venous thromboembolism [20-22]. (See "Evaluation of the patient with established venous thrombosis", section on Screening for hyperhomocysteinemia).